Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide (TA121)
Carmustine implants are recommended as a possible treatment for people with newly diagnosed high-grade glioma only if 90% or more of their tumour has been removed. People should have carmustine implants only at specialist treatment centres under the care of a team of experts, as described in ‘Improving outcomes for people with brain and other central nervous system tumours’ (NICE cancer service guidance 2006; www.nice.org.uk/csgbraincns). Treatment should be supervised by specialist neurosurgeons who:
- spend at least half of their time working in surgery to treat cancers of the brain and spinal cord
- work with a team of other specialists and have access to magnetic resonance imaging (MRI) to help predict before the operation whether it will be possible to remove 90% of the person’s tumour
- have access to technology that helps them precisely locate the tumour during the operation.
Carmustine implants are not recommended for people with newly diagnosed high-grade glioma if less than 90% of their tumour has been removed.
Temozolomide is recommended as a possible treatment for people with newly diagnosed glioblastoma multiforme (a type of high-grade glioma) who have a World Health Organization (WHO) performance status of 0 (they are able to carry out all normal activity without restriction) or 1 (they are restricted in strenuous activity but are able to move around and carry out light work).
- TA121 Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide: guidance (web format)
- TA121 Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide: guidance (MS Word format)
- Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide: review proposal - August 2010
- NICE issues guidance on the use of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
- Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide: Review Decision - October 2010
- Appendix A: Decision paper considered by the Institute's Guidance Executive
This page was last updated: 05 July 2011
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA121 Mewnblaniadau carmustine a temozolomide ar gyfer trin glioma uchelradd sydd newydd ei ganfod: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.